AGP Executive Report
Last update: 11 hours agoEU Pharma Approvals: Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) just cleared a positive CHMP opinion for a perioperative plan in cisplatin-ineligible resectable muscle-invasive bladder cancer, with an EU decision expected in Q3 2026—important for Liechtenstein, Iceland and Norway too. Rare Disease Access: Pharming’s Joenja (leniolisib) won EU marketing authorization as the first approved treatment for APDS, with Germany the first expected launch in Q3 2026. Liechtenstein Finance Focus: Liechtenstein PM Brigitte Haas told finance leaders stability must stay central as global change hits markets and regulation. Cross-Border Deal Flow: Grant Thornton is buying MCA Connect to expand Microsoft-linked digital modernization for manufacturers and distributors. Industry-Policy Backdrop: A BIS notice sets procedures for onshoring agreements to mitigate 100% tariffs on patented pharmaceuticals—while foreign investment trends remain shaky (Switzerland down). Regional Context: The India–Nordic push in Oslo keeps spotlighting green tech and investment links, with Norway’s capital and tech playing a central role.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
